Adenocarcinoma of the Extrahepatic Bile Duct Completed Phase 2 Trials for Sorafenib (DB00398)

IndicationStatusPhase
DBCOND0030457 (Adenocarcinoma of the Extrahepatic Bile Duct)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00238212S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaTreatment